

Supplementary Table 1. Urinalysis and blood test findings

		Acacia group			Placebo group			Group difference (%)	95%CI	χ^2	P value
		n	Applicable participants	Applicable percentage (%)	n	Applicable participants	Applicable percentage (%)				
Urine protein qualitative	4 weeks	32	3	9.4	32	0	0.0	9.4	[-1.0, 19.7]	3.1	0.076
	8 weeks	32	2	6.3	33	2	6.1	0.2	[-11.5, 11.9]	0.0	0.975
	12 weeks	32	1	3.1	33	3	9.1	-6.0	[-17.7, 5.7]	1.0	0.317
	4 weeks post-intervention	32	7	21.9	33	1	3.0	18.8	[2.9, 34.8]	5.3	0.021 *
Urine glucose qualitative	4 weeks	32	2	6.3	32	0	0.0	6.3	[-2.3, 14.8]	2.1	0.151
	8 weeks	32	0	0.0	33	0	0.0	0.0	NA	NA	NA
	12 weeks	32	1	3.1	33	1	3.0	0.1	[-8.3, 8.5]	0.0	0.982
	4 weeks post-intervention	32	0	0.0	33	1	3.0	-3.0	[-9.0, 3.0]	1.0	0.321
Urine pH	4 weeks	32	0	0.0	32	0	0.0	0.0	NA	NA	NA
	8 weeks	32	0	0.0	33	0	0.0	0.0	NA	NA	NA
	12 weeks	32	1	3.1	33	0	0.0	3.1	[-2.9, 9.1]	1.0	0.306
	4 weeks post-intervention	32	1	3.1	33	0	0.0	3.1	[-2.9, 9.1]	1.0	0.306
Urinary occult blood reaction	4 weeks	32	3	9.4	32	0	0.0	9.4	[-1.0, 19.7]	3.1	0.076
	8 weeks	32	0	0.0	33	0	0.0	0.0	NA	NA	NA
	12 weeks	32	1	3.1	33	0	0.0	3.1	[-2.9, 9.1]	1.0	0.306
	4 weeks post-intervention	32	1	3.1	33	0	0.0	3.1	[-2.9, 9.1]	1.0	0.306
White blood cell count	4 weeks	32	0	0.0	32	1	3.1	-3.1	[-9.2, 3.0]	1.0	0.313
	8 weeks	32	1	3.1	33	1	3.0	0.1	[-8.3, 8.5]	0.0	0.982
	12 weeks	32	1	3.1	33	1	3.0	0.1	[-8.3, 8.5]	0.0	0.982
	4 weeks post-intervention	32	1	3.1	33	1	3.0	0.1	[-8.3, 8.5]	0.0	0.982
Red blood cell count	4 weeks	32	1	3.1	32	0	0.0	3.1	[-3.0, 9.2]	1.0	0.313
	8 weeks	32	2	6.3	33	0	0.0	6.3	[-2.1, 14.6]	2.1	0.145
	12 weeks	32	3	9.4	33	1	3.0	6.3	[-5.3, 18.0]	1.1	0.287
	4 weeks post-intervention	32	2	6.3	33	0	0.0	6.3	[-2.1, 14.6]	2.1	0.145
Hemoglobin	4 weeks	32	1	3.1	32	0	0.0	3.1	[-3.0, 9.2]	1.0	0.313
	8 weeks	32	1	3.1	33	0	0.0	3.1	[-2.9, 9.1]	1.0	0.306
	12 weeks	32	2	6.3	33	1	3.0	3.2	[-7.0, 13.4]	0.4	0.536
	4 weeks post-intervention	32	2	6.3	33	1	3.0	3.2	[-7.0, 13.4]	0.4	0.536
Hematocrit	4 weeks	32	1	3.1	32	1	3.1	0.0	[-8.5, 8.5]	0.0	1.000
	8 weeks	32	2	6.3	33	2	6.1	0.2	[-11.5, 11.9]	0.0	0.975
	12 weeks	32	2	6.3	33	1	3.0	3.2	[-7.0, 13.4]	0.4	0.536
	4 weeks post-intervention	32	2	6.3	33	0	0.0	6.3	[-2.1, 14.6]	2.1	0.145
Platelet count	4 weeks	32	2	6.3	32	1	3.1	3.1	[-7.2, 13.5]	0.3	0.554
	8 weeks	32	2	6.3	33	3	9.1	-2.8	[-15.8, 10.1]	0.2	0.667
	12 weeks	32	0	0.0	33	1	3.0	-3.0	[-9.0, 3.0]	1.0	0.321
	4 weeks post-intervention	32	3	9.4	33	4	12.1	-2.7	[-17.8, 12.3]	0.1	0.721
Aspartate aminotransferase	4 weeks	32	1	3.1	32	1	3.1	0.0	[-8.5, 8.5]	0.0	1.000
	8 weeks	32	1	3.1	33	0	0.0	3.1	[-2.9, 9.1]	1.0	0.306
	12 weeks	32	2	6.3	33	2	6.1	0.2	[-11.5, 11.9]	0.0	0.975
	4 weeks post-intervention	32	2	6.3	33	0	0.0	6.3	[-2.1, 14.6]	2.1	0.145
Alanine aminotransferase	4 weeks	32	2	6.3	32	2	6.3	0.0	[-11.9, 11.9]	0.0	1.000
	8 weeks	32	2	6.3	33	2	6.1	0.2	[-11.5, 11.9]	0.0	0.975
	12 weeks	32	3	9.4	33	3	9.1	0.3	[-13.8, 14.4]	0.0	0.968
	4 weeks post-intervention	32	2	6.3	33	1	3.0	3.2	[-7.0, 13.4]	0.4	0.536
γ -glutamyl transpeptidase	4 weeks	32	1	3.1	32	3	9.4	-6.3	[-18.1, 5.6]	1.1	0.302
	8 weeks	32	0	0.0	33	3	9.1	-9.1	[-19.3, 1.1]	3.0	0.081
	12 weeks	32	3	9.4	33	3	9.1	0.3	[-13.8, 14.4]	0.0	0.968
	4 weeks post-intervention	32	3	9.4	33	2	6.1	3.3	[-9.6, 16.3]	0.3	0.616
Total bilirubin	4 weeks	32	1	3.1	32	1	3.1	0.0	[-8.5, 8.5]	0.0	1.000
	8 weeks	32	2	6.3	33	2	6.1	0.2	[-11.5, 11.9]	0.0	0.975
	12 weeks	32	3	9.4	33	3	9.1	0.3	[-13.8, 14.4]	0.0	0.968
	4 weeks post-intervention	32	3	9.4	33	2	6.1	3.3	[-9.6, 16.3]	0.3	0.616

Supplementary Table 1. Urinalysis and blood test findings

		Acacia group			Placebo group			Group difference (%)	95%CI	χ^2	P value
		n	Applicable participants	Applicable percentage (%)	n	Applicable participants	Applicable percentage (%)				
Total protein	4 weeks	32	3	9.4	32	1	3.1	6.3	[-5.6, 18.1]	1.1	0.302
	8 weeks	32	3	9.4	33	1	3.0	6.3	[-5.3, 18.0]	1.1	0.287
	12 weeks	32	2	6.3	33	1	3.0	3.2	[-7.0, 13.4]	0.4	0.536
	4 weeks post-intervention	32	4	12.5	33	0	0.0	12.5	[0.8, 24.2]	4.4	0.036 *
Urea nitrogen	4 weeks	32	3	9.4	32	0	0.0	9.4	[-1.0, 19.7]	3.1	0.076
	8 weeks	32	1	3.1	33	3	9.1	-6.0	[-17.7, 5.7]	1.0	0.317
	12 weeks	32	1	3.1	33	2	6.1	-2.9	[-13.1, 7.3]	0.3	0.573
	4 weeks post-intervention	32	3	9.4	33	1	3.0	6.3	[-5.3, 18.0]	1.1	0.287
Creatinine	4 weeks	32	2	6.3	32	0	0.0	6.3	[-2.3, 14.8]	2.1	0.151
	8 weeks	32	2	6.3	33	0	0.0	6.3	[-2.1, 14.6]	2.1	0.145
	12 weeks	32	1	3.1	33	0	0.0	3.1	[-2.9, 9.1]	1.0	0.306
	4 weeks post-intervention	32	3	9.4	33	0	0.0	9.4	[-0.8, 19.6]	3.2	0.072
Uric acid	4 weeks	32	0	0.0	32	1	3.1	-3.1	[-9.2, 3.0]	1.0	0.313
	8 weeks	32	2	6.3	33	4	12.1	-5.9	[-19.9, 8.2]	0.7	0.414
	12 weeks	32	2	6.3	33	1	3.0	3.2	[-7.0, 13.4]	0.4	0.536
	4 weeks post-intervention	32	1	3.1	33	2	6.1	-2.9	[-13.1, 7.3]	0.3	0.573
Sodium	4 weeks	32	0	0.0	32	0	0.0	0.0	NA	NA	NA
	8 weeks	32	0	0.0	33	0	0.0	0.0	NA	NA	NA
	12 weeks	32	0	0.0	33	0	0.0	0.0	NA	NA	NA
	4 weeks post-intervention	32	0	0.0	33	0	0.0	0.0	NA	NA	NA
Potassium	4 weeks	32	1	3.1	32	1	3.1	0.0	[-8.5, 8.5]	0.0	1.000
	8 weeks	32	2	6.3	33	0	0.0	6.3	[-2.1, 14.6]	2.1	0.145
	12 weeks	32	1	3.1	33	1	3.0	0.1	[-8.3, 8.5]	0.0	0.982
	4 weeks post-intervention	32	2	6.3	33	1	3.0	3.2	[-7.0, 13.4]	0.4	0.536
Chloride	4 weeks	32	0	0.0	32	0	0.0	0.0	NA	NA	NA
	8 weeks	32	0	0.0	33	0	0.0	0.0	NA	NA	NA
	12 weeks	32	0	0.0	33	1	3.0	-3.0	[-9.0, 3.0]	1.0	0.321
	4 weeks post-intervention	32	0	0.0	33	1	3.0	-3.0	[-9.0, 3.0]	1.0	0.321
Serum amylase	4 weeks	32	0	0.0	32	0	0.0	0.0	NA	NA	NA
	8 weeks	32	0	0.0	33	0	0.0	0.0	NA	NA	NA
	12 weeks	32	0	0.0	33	2	6.1	-6.1	[-14.5, 2.3]	2.0	0.157
	4 weeks post-intervention	32	0	0.0	33	0	0.0	0.0	NA	NA	NA
Total cholesterol	4 weeks	32	4	12.5	32	1	3.1	9.4	[-3.8, 22.5]	2.0	0.162
	8 weeks	32	3	9.4	33	2	6.1	3.3	[-9.6, 16.3]	0.3	0.616
	12 weeks	32	8	25.0	33	1	3.0	22.0	[5.2, 38.8]	6.6	0.010 *
	4 weeks post-intervention	32	7	21.9	33	1	3.0	18.8	[2.9, 34.8]	5.3	0.021 *
High-density lipoprotein-cholesterol	4 weeks	32	0	0.0	32	1	3.1	-3.1	[-9.2, 3.0]	1.0	0.313
	8 weeks	32	0	0.0	33	1	3.0	-3.0	[-9.0, 3.0]	1.0	0.321
	12 weeks	32	0	0.0	33	0	0.0	0.0	NA	NA	NA
	4 weeks post-intervention	32	1	3.1	33	1	3.0	0.1	[-8.3, 8.5]	0.0	0.982
Low-density lipoprotein-cholesterol	4 weeks	32	4	12.5	32	0	0.0	12.5	[0.6, 24.4]	4.3	0.039 *
	8 weeks	32	0	0.0	33	0	0.0	0.0	NA	NA	NA
	12 weeks	32	5	15.6	33	0	0.0	15.6	[2.7, 28.6]	5.6	0.018 *
	4 weeks post-intervention	32	6	18.8	33	3	9.1	9.7	[-7.1, 26.5]	1.3	0.260
Triglyceride	4 weeks	32	2	6.3	32	6	18.8	-12.5	[-28.7, 3.7]	2.3	0.131
	8 weeks	32	5	15.6	33	3	9.1	6.5	[-9.4, 22.5]	0.6	0.423
	12 weeks	32	5	15.6	33	5	15.2	0.5	[-17.1, 18.0]	0.0	0.958
	4 weeks post-intervention	32	6	18.8	33	3	9.1	9.7	[-7.1, 26.5]	1.3	0.260
Glucose	4 weeks	32	1	3.1	32	1	3.1	0.0	[-8.5, 8.5]	0.0	1.000
	8 weeks	32	2	6.3	33	2	6.1	0.2	[-11.5, 11.9]	0.0	0.975
	12 weeks	32	1	3.1	33	1	3.0	0.1	[-8.3, 8.5]	0.0	0.982
	4 weeks post-intervention	32	1	3.1	33	2	6.1	-2.9	[-13.1, 7.3]	0.3	0.573

Supplementary Table 1. Urinalysis and blood test findings

		Acacia group			Placebo group			Group difference (%)	95%CI	χ^2	P value
		n	Applicable participants	Applicable percentage (%)	n	Applicable participants	Applicable percentage (%)				
Hemoglobin A1c (NGSP)	4 weeks	32	0	0.0	32	1	3.1	-3.1	[-9.2, 3.0]	1.0	0.313
	8 weeks	32	0	0.0	33	0	0.0	0.0	NA	NA	NA
	12 weeks	32	0	0.0	33	0	0.0	0.0	NA	NA	NA
	4 weeks post-intervention	32	0	0.0	33	0	0.0	0.0	NA	NA	NA

Data are presented as the number of applicable participants and the percentage of groups at each time point, the difference in applicable percentage and its 95% confidence interval (CI), and the chi-square value.

Scr, screening examination; 4, 8, and 12 weeks, after 4, 8, and 12 weeks of intervention; 4 weeks post-intervention, additional post-intervention examination done 4 weeks after the end of the 12-week intervention.

* $P < 0.05$; NA, Not Available

Supplementary Table 2. Physical examination findings

		Acacia group							Placebo group						
		n	Mean	SD	Med	Min	Max	95%CI	n	Mean	SD	Med	Min	Max	95%CI
Height (cm)	Scr	32	163.6	7.3	163.0	149.0	179.5	[161.0, 166.3]	33	163.2	6.8	163.6	151.2	174.3	[160.8, 165.6]
	4 weeks	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	8 weeks	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	12 weeks	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	4 weeks post-intervention	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Body weight (kg)	Scr	32	72.3	6.8	73.1	58.8	88.2	[69.8, 74.7]	33	72.9	8.0	70.1	57.1	87.9	[70.0, 75.7]
	4 weeks	32	72.2	7.2	73.1	56.6	88.3	[69.6, 74.8]	33	72.7	15.3	69.3	0.0	88.7	[67.2, 78.1]
	8 weeks	32	72.0	7.2	73.0	56.6	87.4	[69.4, 74.6]	33	72.0	8.5	70.1	57.4	88.6	[69.0, 75.0]
	12 weeks	32	72.3	7.3	73.7	55.9	88.7	[69.6, 74.9]	33	72.1	8.7	69.9	57.8	89.7	[69.0, 75.2]
	4 weeks post-intervention	32	72.3	6.9	73.4	57.2	86.2	[69.8, 74.8]	33	72.1	8.8	70.1	57.3	89.6	[69.0, 75.3]
Body mass index (kg/m ²)	Scr	32	27.0	1.6	26.5	25.0	29.8	[26.4, 27.5]	33	27.3	1.4	27.3	25.0	29.6	[26.8, 27.8]
	4 weeks	32	27.0	1.6	26.4	24.6	30.3	[26.4, 27.5]	33	27.2	5.0	27.6	0.0	30.0	[25.4, 28.9]
	8 weeks	32	26.8	1.5	26.3	24.5	30.3	[26.3, 27.4]	33	27.0	1.7	27.0	23.9	30.0	[26.4, 27.6]
	12 weeks	32	27.0	1.5	26.6	23.9	29.8	[26.4, 27.5]	33	27.0	1.7	26.9	23.4	29.7	[26.4, 27.6]
	4 weeks post-intervention	32	27.0	1.4	26.6	24.3	30.3	[26.5, 27.5]	33	27.0	1.8	26.8	23.4	29.7	[26.4, 27.6]
Systolic blood pressure (mmHg)	Scr	32	132.4	20.3	130.5	101.0	201.0	[125.1, 139.7]	33	125.6	17.2	122.0	96.0	177.0	[119.5, 131.7]
	4 weeks	32	129.4	19.4	128.0	98.0	179.0	[122.4, 136.4]	33	123.2	27.4	119.0	0.0	167.0	[113.5, 132.9]
	8 weeks	32	128.4	21.3	123.5	96.0	188.0	[120.7, 136.1]	33	125.7	15.1	126.0	99.0	157.0	[120.4, 131.1]
	12 weeks	32	128.6	15.6	131.0	102.0	158.0	[123.0, 134.3]	33	124.7	14.6	120.0	103.0	152.0	[119.5, 129.9]
	4 weeks post-intervention	32	129.5	19.2	130.0	97.0	176.0	[122.5, 136.4]	33	126.3	15.6	126.0	95.0	160.0	[120.8, 131.8]
Diastolic blood pressure (mmHg)	Scr	32	86.7	14.8	85.5	62.0	126.0	[81.4, 92.1]	33	82.5	13.6	82.0	59.0	116.0	[77.7, 87.4]
	4 weeks	32	84.9	13.8	84.5	63.0	115.0	[80.0, 89.9]	33	79.3	17.8	77.0	0.0	110.0	[73.0, 85.6]
	8 weeks	32	84.0	15.2	85.5	56.0	115.0	[78.5, 89.4]	33	81.9	12.4	80.0	59.0	109.0	[77.5, 86.3]
	12 weeks	32	83.5	11.7	85.0	57.0	112.0	[79.3, 87.8]	33	79.9	10.5	78.0	62.0	107.0	[76.2, 83.6]
	4 weeks post-intervention	32	85.7	13.1	85.0	61.0	115.0	[80.9, 90.4]	33	81.4	12.1	80.0	62.0	106.0	[77.1, 85.7]

Data are presented as mean, standard deviation (SD), median (Med), minimum (Min), maximum (Max) and 95% confidence interval (CI).

Scr, screening examination; 4, 8, and 12 weeks, after 4, 8, and 12 weeks of intervention; 4 weeks post-intervention, additional post-intervention examination done 4 weeks after the end of the 12-week intervention.

Supplementary Table 3. Urinalysis findings

		Judgment value	Acacia group		Placebo group	
			Applicable participants	Applicable percentage (%)	Applicable participants	Applicable percentage (%)
Urine protein qualitative	Scr	(-)	31	96.9	32	97.0
		(±)	1	3.1	1	3.0
		(+)	0	0.0	0	0.0
		(2+)	0	0.0	0	0.0
		(3+)	0	0.0	0	0.0
	4 weeks	(-)	29	90.6	32	100.0
		(±)	2	6.3	0	0.0
		(+)	1	3.1	0	0.0
		(2+)	0	0.0	0	0.0
		(3+)	0	0.0	0	0.0
	8 weeks	(-)	30	93.8	30	90.9
		(±)	2	6.3	1	3.0
		(+)	0	0.0	2	6.1
		(2+)	0	0.0	0	0.0
		(3+)	0	0.0	0	0.0
	12 weeks	(-)	31	96.9	29	87.9
		(±)	0	0.0	3	9.1
		(+)	1	3.1	1	3.0
		(2+)	0	0.0	0	0.0
		(3+)	0	0.0	0	0.0
	4 weeks post-intervention	(-)	24	75.0	31	93.9
		(±)	7	21.9	2	6.1
		(+)	0	0.0	0	0.0
		(2+)	0	0.0	0	0.0
		(3+)	1	3.1	0	0.0
Urine glucose qualitative	Scr	(-)	30	93.8	32	97.0
		(±)	1	3.1	0	0.0
		(+)	0	0.0	0	0.0
		(2+)	0	0.0	0	0.0
		(3+)	1	3.1	1	3.0
	4 weeks	(-)	29	90.6	31	96.9
		(±)	0	0.0	0	0.0
		(+)	0	0.0	0	0.0
		(2+)	2	6.3	0	0.0
		(3+)	1	3.1	1	3.1
	8 weeks	(-)	31	96.9	32	97.0
		(±)	0	0.0	0	0.0
		(+)	0	0.0	0	0.0
		(2+)	0	0.0	0	0.0
		(3+)	1	3.1	1	3.0
	12 weeks	(-)	30	93.8	31	93.9
		(±)	0	0.0	1	3.0

Supplementary Table 3. Urinalysis findings

		Judgment value	Acacia group		Placebo group	
			Applicable participants	Applicable percentage (%)	Applicable participants	Applicable percentage (%)
Urine pH	Scr	(+)	0	0.0	0	0.0
		(2+)	1	3.1	0	0.0
		(3+)	1	3.1	1	3.0
		4 weeks post-intervention	(-)	31	96.9	31
		(±)	0	0.0	1	3.0
		(+)	0	0.0	0	0.0
		(2+)	0	0.0	0	0.0
		(3+)	1	3.1	1	3.0
		< 5.0	0	0.0	0	0.0
		5.0 ~ 7.5	32	100.0	33	100.0
Urinary occult blood reaction	Scr	> 7.5	0	0.0	0	0.0
		4 weeks	< 5.0	0	0.0	0.0
		(±)	0	0.0	0	0.0
		5.0 ~ 7.5	32	100.0	32	100.0
		> 7.5	0	0.0	0	0.0
		8 weeks	< 5.0	0	0.0	0.0
		(±)	0	0.0	0	0.0
		5.0 ~ 7.5	32	100.0	33	100.0
		> 7.5	0	0.0	0	0.0
		12 weeks	< 5.0	0	0.0	0.0
		(±)	0	0.0	0	0.0
		5.0 ~ 7.5	31	96.9	33	100.0
		> 7.5	1	3.1	0	0.0
		4 weeks post-intervention	< 5.0	0	0.0	0.0
		(±)	0	0.0	0	0.0
		5.0 ~ 7.5	31	96.9	33	100.0
		> 7.5	1	3.1	0	0.0
		< 5.0	0	0.0	0	0.0
		(±)	0	0.0	0	0.0
		5.0 ~ 7.5	30	93.8	31	93.9
		> 7.5	1	3.1	2	6.1
		(+)	0	0.0	0	0.0
		(2+)	0	0.0	0	0.0
		(3+)	0	0.0	0	0.0
		4 weeks	(-)	29	90.6	32
		(±)	0	0.0	0	0.0
		(+)	1	3.1	0	0.0
		(2+)	0	0.0	0	0.0
		(3+)	2	6.3	0	0.0
		8 weeks	(-)	32	100.0	32
		(±)	0	0.0	0	0.0
		(+)	0	0.0	0	0.0
		(2+)	0	0.0	0	0.0
		(3+)	0	0.0	1	3.0
		12 weeks	(-)	31	96.9	32
		(±)	0	0.0	1	3.0
		(+)	0	0.0	0	0.0
		(2+)	1	3.1	0	0.0
		(3+)	0	0.0	0	0.0
		< 5.0	0	0.0	0	0.0

Supplementary Table 3. Urinalysis findings

	Judgment value	Acacia group		Placebo group	
		Applicable participants	Applicable percentage (%)	Applicable participants	Applicable percentage (%)
4 weeks post-intervention	(-)	30	93.8	33	100.0
	(±)	0	0.0	0	0.0
	(+)	0	0.0	0	0.0
	(2+)	1	3.1	0	0.0
	(3+)	1	3.1	0	0.0

Data are presented as the number of applicable participants and the percentage of groups in each judgment value at each time point.

Scr, screening examination; 4, 8, and 12 weeks, after 4, 8, and 12 weeks of intervention; 4 weeks post-intervention, additional post-intervention examination done 4 weeks after the end of the 12-week intervention.

Supplementary Table 4. Blood test findings

	Category	Lower limit of reference value	Upper limit of reference value	Acacia group								Placebo group								
				n	Mean	SD	Med	Min	Max	95%CI	n	Mean	SD	Med	Min	Max	95%CI			
Glucose (mg/dL)	8 weeks	MIX	30	149	32	135	71	120	42	316	[110, 161]	33	152	151	111	47	934	[98, 205]		
	12 weeks	MIX	30	149	32	127	56	113	41	318	[106, 147]	33	139	80	117	50	439	[111, 168]		
	4 weeks post-intervention	MIX	30	149	32	150	87	108	53	455	[119, 181]	33	129	74	107	51	423	[103, 155]		
	Scr	MIX	70	109	32	94	9	93	81	114	[90, 97]	33	91	10	91	71	116	[88, 95]		
	4 weeks	MIX	70	109	32	93	12	90	72	141	[89, 98]	32	89	9	86	75	115	[86, 93]		
	8 weeks	MIX	70	109	32	95	15	90	80	150	[90, 101]	33	90	11	87	77	120	[86, 94]		
	12 weeks	MIX	70	109	32	92	12	92	75	140	[88, 96]	33	90	10	87	78	119	[86, 93]		
	4 weeks post-intervention	MIX	70	109	32	94	13	93	76	144	[89, 99]	33	88	11	88	63	120	[84, 92]		
	Hemoglobin A1c (NGSP) (%)	Scr	MIX	4.6	6.2	32	5.5	0.4	5.4	4.9	6.9	[5.3, 5.6]	33	5.5	0.4	5.4	4.9	6.5	[5.4, 5.6]	
	4 weeks	MIX	4.6	6.2	32	5.5	0.4	5.4	4.9	7.1	[5.3, 5.6]	32	5.5	0.4	5.5	4.9	6.4	[5.3, 5.6]		
	8 weeks	MIX	4.6	6.2	32	5.5	0.4	5.4	4.9	6.8	[5.3, 5.6]	33	5.5	0.3	5.5	4.9	6.4	[5.4, 5.6]		
	12 weeks	MIX	4.6	6.2	32	5.5	0.4	5.4	4.9	6.9	[5.4, 5.7]	33	5.5	0.3	5.5	4.9	6.6	[5.4, 5.6]		
	4 weeks post-intervention	MIX	4.6	6.2	32	5.5	0.4	5.5	5.0	7.3	[5.4, 5.7]	33	5.5	0.4	5.5	4.9	6.6	[5.4, 5.6]		

Data are presented as mean, standard deviation (SD), median (Med), minimum (Min), maximum (Max) and 95% confidence interval (CI).

Scr, screening examination; 4, 8, and 12 weeks, after 4, 8, and 12 weeks of intervention; 4 weeks post-intervention, additional post-intervention examination done 4 weeks after the end of the 12-week intervention.

MIX: both male and female; M: male; F: female

